Abstract
[30] Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058–65. [31] Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Am Med Assoc 2009;301:39–51. [32] Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64: 537–41. [33] Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674–85. [34] Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314–7. [35] Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007;28:763–9.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
